EMERYVILLE, Calif., May 25, 2022
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a
commercial-stage biopharmaceutical company developing and
commercializing innovative vaccines, today announced that
Ryan Spencer, Chief Executive
Officer and Kelly MacDonald, Chief
Financial Officer, will participate in a fireside chat during the
William Blair 42nd Annual Growth Stock Conference in Chicago, Illinois on Monday June 6, 2022 at 4:40 p.m. C.T.
A live webcast of the presentation can be accessed through the
"Events & Presentations" page on the "Investors" section of the
Company's website at
https://investors.dynavax.com/events-presentations and a replay
will be available following the event.
About Dynavax
Dynavax is a commercial-stage
biopharmaceutical company developing and commercializing innovative
vaccines to help protect the world against infectious diseases. The
Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis
B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S.
and the European Union for the prevention of infection caused by
all known subtypes of hepatitis B virus in adults age 18 years and
older, and CpG 1018 adjuvant, currently used in multiple adjuvanted
COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a
premier vaccine adjuvant through global research collaborations and
partnerships. Current collaborations are focused on adjuvanted
vaccines for COVID-19, seasonal influenza, universal influenza,
plague, shingles and Tdap. For more information about our marketed
products and development pipeline, visit www.dynavax.com and follow
Dynavax on LinkedIn.
Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-william-blair-42nd-annual-growth-stock-conference-301555194.html
SOURCE Dynavax Technologies